Guardant360 CDx assay is the first liquid biopsy companion diagnostic test that uses next-generation sequencing technology to receive FDA approval. The assay uses NGS technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in a deadly form of metastatic non-small cell lung cancer.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
